Dimerix CEO on surprising Phase II data

Mike Ward, global director of content for Informa Pharma Insights, chats with Kathy Harrison, CEO of Dimerix, about the company's recent Phase IIa trial for DMX-200 in patients with chronic kidney disease. Harrison outlines the company's recent study that turned up surprising data in patients with diabetic nephropathy. Australia-based Dimerix will now power its next clinical trial for DMX-200 to focus on this indication. Harrison also talks about the company’s wider-strategy changes and the potential for licensing a DMX-200 diabetic nephropathy program.